VIDEO: Early data on optogenetic therapy in Stargardt disease promising

ByAllen C. Ho, MD

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Allen C. Ho, MD, FASRS, discusses 6-month data on MCO-010 optogenetic therapy in patients with Stargardt disease.

“Patients are seeing clinically meaningful improvements in vision, improvements in visual field and Octopus visual field sensitivity, and reporting that they are seeing better patient-reported outcomes that are beneficial,” Ho said.

MCO-010 demonstrated no serious adverse events in the cohort of six patients, he said.

Published by:

Sources/Disclosures

Collapse

Source:

Ho A. MCO-010 optogenetic therapy for severe vision loss in Stargardt disease: 6-month outcomes from the phase 2 STARLIGHT trial. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.

Disclosures: Ho reports being a scientific advisor for Nanoscope Therapeutics and other companies in the gene therapy space.

American Society of Retina Specialists Meeting

Read more

VIDEO: Early data on optogenetic therapy in Stargardt disease promising

Related Content